Abstract Number: 2834 • 2018 ACR/ARHP Annual Meeting
The Presence of Anti-Rituximab Antibodies Predicts Infusion-Related Reactions in Patients with Systemic Lupus Erythematosus
Background/Purpose: Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody that is commonly used in the treatment of severe and refractory SLE. Although generally well…Abstract Number: 24 • 2018 ACR/ARHP Annual Meeting
Rituximab Induces an Early Re-Assessment of the Immune and Vascular Systems in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Background/Purpose: While the role of Rituximab (RTX) in controlling the clinical manifestations of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) has been documented, the…Abstract Number: 2682 • 2018 ACR/ARHP Annual Meeting
Novel Antibody Against Commensal Bacterial Antigen in Prediction of the Response of Rituximab in Systemic Lupus Erythematosus
Background/Purpose: Streptoccocal infections can cause rheumatic fever sharing clinical presentations similar to SLE. Whether oral commensal streptococci could induce cross-reactive and pathogenic antibodies remained unknown.…Abstract Number: 890 • 2017 ACR/ARHP Annual Meeting
Synergetic B-Cell Immunomodulation with Rituximab and Belimumab Combination Treatment in Severe, Refractory SLE
Background/Purpose: Neutrophil extracellular traps (NETs) are auto-antigenic DNA strands and potentially give rise to SLE-specific autoantibodies that can deposit in glomeruli. It has been shown…Abstract Number: 2597 • 2017 ACR/ARHP Annual Meeting
Explorer Study: Rituximab Use in Systemic Lupus Erythematosus, a New Look on Old Data
Background/Purpose: Even if randomized trials EXPLORER and LUNAR failed to prove the superiority of rituximab versus placebo in patients with systemic lupus erythematosus, several encouraging…Abstract Number: 2602 • 2017 ACR/ARHP Annual Meeting
Identification of Clinical and Serological Predictive Factors of Response to Rituximab Treatment in Systemic LUPUS Erythematosus (SLE) Patients
Background/Purpose: Response to Rituximab (RTX) varies significantly between Systemic Lupus Erythematosus (SLE) patients. Ethnicity may play a role in these differences, and a possible relationship…Abstract Number: 739 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Rituximab in the Treatment of Refractory Systemic Lupus Erythematosus: Results from a National Register
Background/Purpose: Response to the anti-CD20 agent rituximab (RTX) in SLE is variable but it is still widely used for refractory SLE. Our aim was to…Abstract Number: 762 • 2016 ACR/ARHP Annual Meeting
Pragmatic Treatment of Patients with Systemic Lupus Erythematosus with Rituximab: Long-Term Effects on Serum Immunoglobulins
Background/Purpose: B cell depletion therapy based on rituximab is a therapeutic option for refractory disease in patients with Systemic Lupus Erythematosus (SLE). Hypogammaglobulinemia can be…Abstract Number: 773 • 2016 ACR/ARHP Annual Meeting
Risk Factors for Severe Infections in Rituximab Treated Patients: Comparison of Systemic Lupus Erythematosus and Inflammatory Myositis
Background/Purpose: The use of Rituximab (RTX) in patients with autoimmune diseases has been associated with an increased incidence of infection and risk factors for this…Abstract Number: 777 • 2016 ACR/ARHP Annual Meeting
a Singlecenter Experience of Rituximab Treatment in 86 Patients with Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with diverse clinical and serological manifestations. B-cell-targeted therapies have been promising new treatments for SLE.…Abstract Number: 781 • 2016 ACR/ARHP Annual Meeting
The Use of Rituximab in Newly Diagnosed Systemic Lupus Erythematosus Patients: Long Term Steroid Saving Capacity and Clinical Effectiveness
Background/Purpose: To assess the long term steroid saving capacity and clinical effectiveness of B-cell depletion therapy (BCDT) in newly diagnosed SLE patients. Methods: Sixteen female…Abstract Number: 1112 • 2015 ACR/ARHP Annual Meeting
Obinutuzumab Outperforms Rituximab at Inducing B-Cell Cytotoxicity in Vitro through Fc-Mediated Effector Mechanisms in Rheumatoid Arthritis and Systemic Lupus Erythematosus
Background/Purpose: Obinutuzumab (OBZ, a Type II anti-CD20 monoclonal antibody [mAb] with afucosylated Fc portion and enhanced affinity for Fcγ receptor III) is more efficient than…Abstract Number: 2903 • 2015 ACR/ARHP Annual Meeting
Late-Onset Neutropenia Following Rituximab Treatment in Patients with Systemic Lupus Erythematosus
Background/Purpose: The incidence and clinical consequences of rituximab-mediated late-onset neutropenia (LON) have been studied in various diseases, but data from Systemic Lupus Erythematosus (SLE) are…Abstract Number: 989 • 2014 ACR/ARHP Annual Meeting
Fcgamma Receptor IIb Facilitates Rapid Internalisation of Rituximab (type 1 anti-CD20 antibody) in B Cells from Patients with RA and SLE and Contributes to Less Efficient B Cell Lysis Than Type 2 Anti-CD20 Antibodies, in Vitro
Background/Purpose Incomplete B-cell depletion using rituximab (RTX) is associated with poor clinical response in some individuals with RA and SLE, in particular. However, the precise…Abstract Number: 2164 • 2013 ACR/ARHP Annual Meeting
Rituximab In The Treatment Of Children With Systemic LUPUS Erythematosus: ONE Year Analysis Of 12 Patients
Background/Purpose: Treatment of childhood systemic lupus erythematosus (SLE) is an ongoing problem because of the severity of the disease in some patients and the side-effects…
ACR Meeting Abstracts